Home / Market News / $ASND
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Wedbush Raises Price Target on Ascendis Pharma to $346 From $327

Nov 13, 2026, 1:05 PM UTC · Primary ticker $ASND

Wedbush Securities has increased its price target for Ascendis Pharma to $346 from $327, while maintaining an Outperform rating. This adjustment follows the company's Q3 2026 earnings report, suggesting a positive re-evaluation of its future prospects by the analyst firm.

Wedbush Securities has raised its price target on Ascendis Pharma (ASND) from $327 to $346, while reiterating an Outperform rating. This revision comes after the company's third-quarter 2026 earnings report, indicating that Wedbush analysts likely found positive elements in the financial results or future outlook that warranted an upward adjustment. For traders, this signals a potential positive sentiment shift from a notable analyst firm, which could lead to short-term upward price momentum for ASND. The long-term implications depend on whether other analysts follow suit and if the company's fundamentals continue to support this increased valuation. A key opportunity for traders is to capitalize on any immediate positive reaction to this analyst upgrade.

$ASND positive Price target increase by Wedbush
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.